The effectiveness of botulinum toxin type A preparations in the consequences of gunshot wounds (clinical case)

Background. The events of the last two years of a Special Military Operation have obliged doctors of all specialties to re-evaluate the methods of diagnosis, treatment, and anesthesia of patients with the consequences of gunshot wounds. The article presents a clinical case of a severe pain syndrome (piriform muscle syndrome) due to a gunshot wound and its treatment using botulinum therapy. Botulinum toxin type A has a unique analgesic effect, which has expanded the scope of its application in clinical practice.

Objective. The purpose of the study was to evaluate the effectiveness of botulinum toxin type A preparations in severe pain syndrome due to gunshot wounds.

Results. As a result of the treatment with botulinum toxin type A, a pronounced positive dynamics of pain relief was obtained in case of piriform muscle syndrome, which developed as a result of the consequences of a gunshot wound.

Conclusion. Piriform muscle syndrome is a disorder that often manifests as a clinical picture of different pathologies. A late diagnosis or inadequate therapy can lead to the pathological changes in the sciatic nerve. The key to the effectiveness of the method used is the early detection of such disorder. Currently, the range of preparations for the treatment of pain syndrome is quite wide, but only a methodologically proper injection can increase the effectiveness of piriform muscle syndrome treatment and reduce the risk of complications, which is impossible without the use of imaging techniques. Thus, we believe that injections into the area of the piriform muscle under the visualization control should become the method of choice in the treatment of pain of such localization.

1. Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neuro Toxicology. 2005; 26: 785-793.

2. Goadsby P. J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56.

3. Gobel H., Heinze A., Heinze-Kuhn K., Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001; 91: 195-199.

4. Wheeler A. H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache. 1998; 38 (6): 468-471.

5. Silberstein S. D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001; 2 (10): 1649-1654.

6. Aoki K. R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003; 43 (Suppl 1): 9-15.

7. Dressler D., Saberi F. A., Barbosa E. R. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005; 63: 180-185.

8. Durham P. L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011; 51 (10): 1573-1577.

9. Gazerani P., Staahl C., Drewes A. M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on cap-saicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006; 122 (3): 315-325.

10. Gazerani P., Pedersen N. S., Staahl C., et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141 (1-2): 60-69.

11. Purkiss J., Welch M., Doward S., Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000; 59 (11): 1403-1406.

12. Welch M. J., Purkiss J. R., Foster K. A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38 (2): 245-258.

13. Aoki K. R. Evidence for antinociceptive activity of botulinumtoxin type A in pain management. Headache. 2003; 43 (Suppl 1): 9-15.

14. Aoki K. R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26 (5): 785-793.

15. Gazerani P., Pedersen N. S., Staahl C., et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141 (1-2): 60-69.

16. Артеменко А. Р., Орлова О. Р. Ботулинический токсин типа А: расширение возможностей терапии первичных головных болей. Врач. 2007; 5: 40-43.

17. Santamato A., Micello M. F., Valeno G., Beatrice R., Cinone N., Baricich A., Picelli A., Panza F., Logroscino G., Fiore P., Ranieri M. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins (Basel). 2015; 7 (8): 3045-3056. https://doi.org/10.3390/toxins7083045.

18. Al-Al-Shaikh M., Michel F., Parratte B., Kastler B., Vidal C., Aubry S. An MRI evaluation of changes in piriformis muscle morphology induced by botulinum toxin injections in the treatment of piriformis syndrome. Diagn. Interv. Imaging. 2015; 96 (1): 37-43. https://doi.org/10.1016/j.diii.2014.02.015.

19. Rodriguez-Pinero M., Vidal Vargas V., Jimenez Sarmiento A. S. Long-Term Effi cacy of Ultrasound-Guided Injection of IncobotulinumtoxinA in Piriformis Syndrome. Pain Med. 2018; 19 (2): 408-411. https://doi.org/10.1093/pm/pnx135

20. Ripellino P., Cianfoni A., Izzo M. G. A., Gobbi C. Relapsing piriformis syndrome treated with botulinum toxin injections. Brit.med. J. Case Rep. 2019; 12: e230981. https://doi.org/10.1136/bcr-2019-230981.

21. Fishman L. M., Wilkins A. N., Rosner B. Electrophysiologically identifi ed piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017; 56 (2): 258-263. https://doi.org/10.1002/mus.25504.

22. Santamato A., Micello M. F., Valeno G., Beatrice R., Cinone N., Baricich A., Picelli A., Panza F., Logroscino G., Fiore P., Ranieri M. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins (Basel). 2015; 7 (8): 3045-3056. https://doi.org/10.3390/toxins7083045.

23. Fabregat G., Rosello M., Asensio-Samper J. M., Villaneuva-Perez V. L., Martinez-Sanjuan V., De Andres J., Eichenberger U. Computertomographic verifi cation of ultrasound-guided piriformis muscle injection: a feasibility study. Pain Physic. 2014; 17 (6): 507-513.

24. Koh E., Webster D., Boyle J. Case report and review of the potential role of the Type A piriformis muscle in dynamic sciatic nerve entrapment variant of piriformis syndrome. Surg. Radiol. Anat. 2020; 42 (10): 1237-1242. https://doi.org/10.1007/s00276-020-02440-8.

25. Fritz J., Chhabra A., Wang K. C., Carrino J. A. Magnetic resonance neurography-guided nerve blocks for the diagnosis and treatment of chronic pelvic pain syndrome. Neuroimag. Clin. N. Amer. 2014; 24 (1): 211-234. https://doi.org/10.1016/j.nic.2013.03.028.

26. Fishman L. M., Wilkins A. N., Rosner B. Electrophysiologically identifi ed piriformis syndrome is successfully treated with incobotulinum toxin a and physical therapy. Muscle Nerve. 2017; 56 (2): 258-263. https://doi.org/10.1002/mus.25504.